Clinical Trial Update: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]

View source ↗

Summary

This update reports on a completed Phase 1/2 study evaluating the safety, pharmacokinetics, pharmacodynamics, and dose expansion of PXS-5505 in patients with my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• PXS-5505 (PXS-5505)

Snippet

Sponsor: Syntara | Conditions: Myelofibrosis | Phase 1, Phase 2 | Status: COMPLETED